Curis Lifesciences Charts a New Growth Path with Uninova, Export Markets and Branded Pharma Expansion

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

Curis Lifesciences Limited is entering a new phase of growth as it expands across domestic branded pharmaceuticals, international markets and contract manufacturing, with its 51% acquisition of Uninova Lifesciences Pvt. Ltd. adding a new dimension to the company’s evolving business strategy.

The company’s growth roadmap is built around three complementary opportunities — strengthening its merchant export business in Kenya, establishing a long-term pharmaceutical presence in Nigeria, and scaling its domestic branded pharmaceutical business through Uninova. Together, these initiatives are aimed at expanding the company’s product portfolio, geographic presence and revenue base while creating a more diversified business model.

The acquisition of a 51% stake in Uninova Lifesciences gives Curis access to an established pharmaceutical marketing platform, distribution relationships and an expanding portfolio of branded products. Uninova currently has approximately 50 products under its own brand portfolio and plans to launch around 12 additional products in the near term, with an objective of exceeding 100 products by the end of the year.

As part of this portfolio expansion, Uninova has entered the injectable segment with the launch of six products across four key molecules — Gentamicin, Dexamethasone, Ondansetron and Paracetamol . The portfolio includes Novagent, Novagent Plus, Novadex, Novadex Forte, Ondanova and Novapar Forte.

The injectable expansion is being pursued through a third-party manufacturing model, allowing Uninova to broaden its product portfolio while leveraging its existing marketing and distribution ecosystem without requiring immediate investment in additional manufacturing infrastructure.

Uninova’s growth ambitions are also reflected in its financial targets. The business generated approximately INR 5.43 crore in turnover in the previous year and is targeting approximately INR 7 crore in the current year . Own-brand product sales are expected to rise from approximately INR 0.75 crore to INR 3 crore , reflecting a greater focus on branded pharmaceutical products.

Commenting on the company’s growth strategy, Mr. Dharmesh Patel, Chairman & Managing Director of Curis Lifesciences Limited said, “We are focused on building a diversified pharmaceutical platform with multiple growth engines across domestic branded pharmaceuticals, contract manufacturing and international markets. The expansion through Uninova strengthens our branded product presence and gives us an established platform to expand our portfolio, including new segments such as injectables. At the same time, our initiatives in Kenya and Nigeria are aimed at creating near-term export opportunities while building a foundation for long-term international growth.”

He further added, “Our approach is to leverage our existing capabilities, partnerships and marketing ecosystem to pursue growth in a capital-efficient manner.